Details for Patent: 5,798,092

Title:	Derivatized DTPA complexes pharmaceutical agents containing these compounds, their use, and processes for their production
Abstract:	Compounds of general Formula I ##STR1## wherein Z.sup.1 and Z.sup.2 in each case independently mean the residue wherein m and n means the numbers 0-20, k, l, q and r means the numbers 0 and 1, and R means a hydrogen atom, an optionally OR.sup.1 -substituted C.sub.1 -C.sub.6 -alkyl residue, or a CH.sub.2 COOR.sup.1 group with R.sup.1 meaning a hydrogen atom, a C.sub.1 -C.sub.6 -alkyl residue, or a benzyl group, with the proviso that at least two substituents X stand for a metal ion equivalent; that one of the substituents Z.sup.1 and Z.sup.2 stands for a hydrogen and the other is not H; that--if n and l each means the number 0--k and r do not simultaneously mean the number 1; that --(O).sub.r --R is not --OH; and that Z.sup.1 and Z.sup.2 are not --CH.sub.2 --C.sub.6 H.sub.4 --O--CH.sub.2 --COOCH.sub.2 C.sub.6 H.sub.5 or --CH.sub.2 --C.sub.6 H.sub.4 --O--(CH.sub.2).sub.5 --COOCH.sub.2 C.sub.6 H.sub.5, are valuable pharmaceutical agents, e.g., for NMR or X-ray imaging.
Inventor(s):	Schmitt-Willich; Heribert (Berlin, DE), Platzek; Johannes (Berlin, DE), Gries; Heinz (Berlin, DE), Schumann-Giampieri; Gabrielle (Berlin, DE), Weinmann; Hanns-Joachim (Berlin, DE), Vogler; Hubert (Berlin, DE), Deutsch; Julius (Berlin, DE), Conrad; Juergen (Berlin, DE)
Assignee:	Schering Aktiengesellschaft (DE)
Filing Date:	Jun 05, 1995
Application Number:	08/461,746
Claims:	1. A compound of the formula ##STR4## wherein one of Z.sup.1 and Z.sup.2 is H and the other is wherein m and n, independently, are each 0-20, k, l, q and r are each, independently, 0 or 1, R is H, C.sub.1 -C.sub.6 -alkyl, OR.sup.1 -substituted C.sub.1 -C.sub.6 -alkyl or CH.sub.2 COOR.sup.1, R.sup.1 is H, C.sub.1 -C.sub.6 -alkyl or benzyl; and X is, in each case, a hydrogen atom or a metal ion equivalent of an element of atomic number 21-29, 42, 44 or 57-83; with the provisos that; at least two of the substituents X represent a metal ion equivalent; when n and l each are 0, then k and r are not simultaneously 1; --(O).sub.r --R is not OH; Z.sup.1 and Z.sup.2 are not --CH.sub.2 --C.sub.6 H.sub.4 --O--CH.sub.2 --COOCH.sub.2 C.sub.6 H.sub.5, --CH.sub.2 --C.sub.6 H.sub.5, --CH.sub.2 --C.sub.6 H.sub.4 --OCH.sub.3 or --CH.sub.2 --C.sub.6 H.sub.4 --O--(CH.sub.2).sub.5 --COOCH.sub.2 C.sub.6 H.sub.5 ; Z.sup.1 is not phenyl when Z.sup.2 is H; and at least one of q and l is 1; or a physiologically acceptable salt thereof with an inorganic and/or organic base, an amino acid or amino acid amide. 2. A compound of claim 1, wherein Z.sup.1 is hydrogen and Z.sup.2 is --(CH.sub.2).sub.m --(C.sub.6 H.sub.4).sub.q --(O).sub.k --(CH.sub.2).sub.n --(C.sub.6 H.sub.4).sub.l --(O).sub.r --R. 3. A compound of claim 1, wherein Z.sup.2 is hydrogen and Z.sup.2 is --(CH.sub.2).sub.m --(C.sub.6 H.sub.4).sub.q --(O).sub.k --(CH.sub.2).sub.n --(C.sub.6 H.sub.4).sub.l --(O).sub.r --R. 4. A compound of claim 1, wherein Z.sup.1 is --CH.sub.2 --C.sub.6 H.sub.4 --O--CH.sub.2 --C.sub.6 H.sub.4 --OCH.sub.3, --CH.sub.2 O--CH.sub.2 --C.sub.6 H.sub.5, --CH.sub.2 --C.sub.6 H.sub.4 --O--CH.sub.2 --COOH, --CH.sub.2 --C.sub.6 H.sub.4 --OC.sub.2 H.sub.5, --CH.sub.2 --C.sub.6 H.sub.4 --OC.sub.4 H.sub.9 or --CH.sub.2 --C.sub.6 H.sub.4 --O--CH.sub.2 --C.sub.6 H.sub.5. 5. A compound of claim 1, wherein Z.sup.2 is --CH.sub.2 --C.sub.6 H.sub.4 --O--CH.sub.2 --C.sub.6 H.sub.4 --OCH.sub.3, --CH.sub.2 O--CH.sub.2 --C.sub.6 H.sub.5, --CH.sub.2 --C.sub.6 H.sub.4 --O--CH.sub.2 --COOH, --CH.sub.2 --C.sub.6 H.sub.4 --OC.sub.2 H.sub.5, --CH.sub.2 --C.sub.6 H.sub.4 H.sub.9 or --CH.sub.2 --C.sub.6 H.sub.4 --O--CH.sub.2 --C.sub.6 H.sub.5. 6. A compound of claim 1, wherein at least three X groups represent a Gd ion. 7. A compound of claim 4, wherein at least three X groups represent a Gd ion. 8. A compound of claim 5, wherein at least three X groups represent a Gd ion. 9. A compound of claim 1, wherein said compound is: gadolinium complex of 3,6,9-triaza-3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-[4-(4-methoxybenzylo xy)benzyl]undecadenioic acid or a physiologically acceptable salt thereof; gadolinium complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl-4-benzyloxymethylundecanedioic acid or a physiologically acceptable salt thereof; gadolinium complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl-4-carboxymethoxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof; gadolinium complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl-4-ethoxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof; europium complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof; iron complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof; gadolinium complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl-4-butoxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof; europium complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-butoxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof; iron complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-butoxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof; gadolinium complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl-4-(4-benzyloxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof; europium complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-benzyloxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof; or iron complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-benzyloxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof. 10. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutical acceptable carrier. 11. In a method of NMR imaging a patient comprising administering an NMR contrast agent to said patient, the improvement wherein: said contrast agent exhibits both renal and extrarenal excretion, and said contrast agent provides enhanced contrast of the renal system, the gastrointestinal tract and the liver, gall bladder, and bile ducts. 12. A compound according to claim 1, wherein at least two of the X groups represent a metal ion of atomic number 21-29, 42, 44 or 58-70. 13. A compound according to claim 1, wherein two of the X groups represent manganese(II), iron(II), cobalt(II) or copper(II); or three of the X groups represent chromium(III), praseodymium(III), neodymium(III), samarium(III), ytterbium(III), gadolinium(III), terbium(III), dysprosium(III), holmium(III), erbium(III), or iron(III). 14. A compound according to claim 1, wherein Z.sup.1 is --C.sub.6 H.sub.4 --O--C.sub.2 H.sub.5 or --C.sub.2 H.sub.4 --C.sub.6 H.sub.4 --O--C.sub.2 H.sub.5. 15. A compound according to claim 1, wherein said compound is gadolinium complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxyphenyl)undecanedioic acid or a physiologically acceptable salt thereof. 16. A compound according to claim 1, wherein said compound is a complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4ethoxyphenylethyl)undecanedioic acid and a metal ion of atomic number 21-29, 42, 44 or 57-83, or a physiologically acceptable salt thereof. 17. A compound according to claim 1, wherein R is C.sub.1-6 -alkyl or C.sub.1-6 -alkyl substituted by --OR.sup.1. 18. A compound according to claim 1, wherein one of Z.sup.1 and Z.sup.2 is --CH.sub.2 --C.sub.6 H.sub.4 --O--(CH.sub.2).sub.n --(C.sub.6 H.sub.4).sub.1 --(O).sub.r --R. 19. A compound according to claim 1, wherein one of Z.sup.1 and Z.sup.2 is --(CH.sub.2).sub.m --C.sub.6 H.sub.4 --O--CH.sub.2 --C.sub.6 H.sub.4 --(O).sub.r --R. 20. A compound according to claim 1, wherein the X groups which do not represent a metal ion equivalent of atomic number 21-29, 42, 44 or 57-83 are individually lithium, potassium or sodium, or two such X groups are calcium or magnesium. 21. A compound according to claim 1, wherein the groups which are not a metal ion equivalent of an element of atomic number 21-29, 42, 44 or 57-83 represent a salt with ethanolamine, diethanolamine, morpholine, glucamine, N,N-dimethylglucamine, N-methylglucamine, lysine, arginine, ornithine, lysine methylamide, glycine ethylamide or serine methylamide. 22. A composition according to claim 10, wherein the amount of said compound is 50 .mu.mol/l-2 mol/l. 23. A composition according to claim 10, wherein the amount of said compound is 100 mmol/l-1 mol/l. 24. A compound of claim 4, wherein Z.sup.1 is --CH.sub.2 --C.sub.6 H.sub.4 --O--CH.sub.2 --C.sub.6 H.sub.4 --OCH.sub.3, --CH.sub.2 --O--CH.sub.2 --C.sub.6 H.sub.5 or --CH.sub.2 --C.sub.6 H.sub.4 O--CH.sub.2 --COOH. 25. A compound of claim 4, wherein Z.sup.2 is --CH.sub.2 --C.sub.6 H.sub.4 --O--CH.sub.2 --C.sub.6 H.sub.4 --OCH.sub.3, --CH.sub.2 --O--CH.sub.2 --C.sub.6 H.sub.5 or --CH.sub.2 --C.sub.6 H.sub.4 O--CH.sub.2 --COOH. 26. A compound according to claim 14, wherein Z.sup.2 is --C.sub.6 H.sub.4 --OC.sub.2 H.sub.5. 27. A compound according to claim 1, wherein Z.sup.1 is --C.sub.6 H.sub.4 --OC.sub.2 H.sub.5 or --C.sub.2 H.sub.4 --C.sub.6 H.sub.5 OC.sub.2 H.sub.5. 28. A compound according to claim 26, wherein two of the X groups represent manganese(II), iron(II), cobalt(II), or copper(II); or three of the X groups represent chromium(III), praseodymium(III), neodmium(III), samarium(III), ytterbium(III), gadolinium(III) terbium(III), dysprosium(III), holmium(III), erbium(III), or iron(III). 29. A compound according to claim 10, wherein said composition further comprises at least one physiologically acceptable buffer, at least one complexing agent, at least one electrolyte, and/or at least one antioxidant. 30. A compound according to claim 10, wherein said carrier is an aqueous medium and said composition contains 50 .mu.mol/l-2 mol/l of said compound. 31. A compound according to claim 10, wherein said carrier is an aqueous medium and said composition contains 100 mmol/l-1 mol/l of said compound. 32. A method according to claim 11, wherein said NMR contrast agent is administered intravenously. 33. A method according to claim 11, wherein said NMR contrast agent is administered in a dose of 1 .mu.mol/kg-5 mmol/kg. 34. A method according to claim 11, wherein said NMR contrast agent is administered in a dose of 10 .mu.mol/kg-0.5 mmol/kg. 35. In a method of conducting radiation therapy of a patient comprising administering a radioactive metal ion to the patient, the improvement wherein the radioactive metal ion is administered in the form of a compound of claim 1.